Compare ADMA Biologics Inc (ADMA) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Gemini Space Station Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Gemini Space Station Inc trades at $4.02 (market cap $517.11M). The key difference: ADMA Biologics Inc is far larger — about 4.2× Gemini Space Station Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | GEMI | |
|---|---|---|
Market Cap | $2.18B | $517.11M |
Sector | Health | Technology |
52-Week High | $20.38 | $32.52 |
52-Week Low | $7.60 | $3.90 |
Enterprise Value | $2.25B | $507.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.
The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
